Fas Promoter –670 Polymorphism Is Associated with Development of Anti-RNP Antibodies in Systemic Lupus Erythematosus

YOUNG HO LEE, YE REE KIM, JONG DAE JJ, JEONGWON SOHN, and GWAN GYU SONG

ABSTRACT. Objective. To evaluate whether the polymorphism of Fas promoter –670 is associated with susceptibility to systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and their clinical features.

Methods. A polymerase chain reaction of a genomic DNA-restriction fragment length polymorphism was used to determine genotypes of the Fas promoter –670 in 87 patients with SLE, 87 with RA, and 87 healthy controls. A second cohort of SLE patients (n = 85) was included. Clinical manifestations were analyzed in each patient and correlated with the genotypes.

Results. The genotype distribution of the Fas promoter –670 did not differ between patients with SLE and control subjects (AA, GA, GG genotypes 31, 54, 15% vs 30, 55, 15% controls, respectively; chi-squared = 0.03, 2 df, p = 0.99) and between RA patients and controls (AA, GA, GG genotypes 38, 44, 18% vs 30, 55, 15% controls, respectively; chi-squared = 2.30, 2 df, p = 0.32).

Regarding the clinical status of lupus patients according to Fas promoter –670 genotypes, there was no significant difference in age at onset, anti-dsDNA titer, C3, C4 level, renal involvement, number of American College of Rheumatology (ACR) criteria met, SLE Disease Activity Index, SLE International Collaborating Clinics/ACR Damage Index, or autoantibody profiles. However, the frequency of anti-RNP antibody was significantly different in the AA, GA, and GG groups (71, 25, 30%; chi-squared = 13.29, 2 df, p = 0.001). To confirm this finding, the Fas promoter –670 genotype was examined in a second cohort of SLE patients (n = 85). The result in the second cohort replicated the association shown in the first. In patients with RA, there was no significant difference in clinical and laboratory findings according to the Fas promoter –670 genotypes.

Conclusion. Our data suggest that the Fas promoter –670 polymorphism is associated with development of anti-RNP antibodies in SLE. (J Rheumatol 2001;28:2008–11)

Key Indexing Terms: SYSTEMIC LUPUS ERYTHEMATOSUS FAS POLYMORPHISMS RHEUMATOID ARTHRITIS

Systemic lupus erythematosus (SLE) is the prototype of human autoimmune diseases and a disorder of generalized autoimmunity with unknown etiology, characterized by multisystemic organ involvement, polyclonal B cell activation, and production of autoantibodies. One possible explanation for the pathogenesis of SLE is a failure of apoptosis of self-reactive T cells. Tolerance to self-antigens can be broken and can result in autoimmune diseases such as SLE.
A recently described polymorphism within the Fas gene promoter is an A to G substitution at nucleotide position –670 in the enhancer region. This polymorphism abolishes the binding site of the nuclear transcription element, gamma-activated sequence (GAS). The function of the polymorphism remains unclear, but its location, situated on a consensus sequence of the GAS, implies that it might be associated with susceptibility to SLE and RA and their clinical features.

**MATERIALS AND METHODS**

**Patients and controls.** Eighty-seven Korean patients with SLE (83 female, 4 male, age 16 to 62 yrs, mean 36), 87 Korean patients with RA (73 female, 14 male, age 16–75 yrs, mean 45), and 87 ethnically matched healthy controls were enrolled in this study. The patients were recruited from the Rheumatology Clinic of Korea University Guro Hospital. A second cohort of SLE patients (82 female, 3 male, age 18 to 63 yrs, mean 37) was recruited from the Rheumatology Clinic of Korea University Anam Hospital. All patients fulfilled the classification criteria of the American College of Rheumatology (ACR) for SLE or RA. Eighty-seven healthy individuals with no history of an autoimmune disease were recruited as controls (68 female, 19 male, age 18–70 yrs, mean 41). SLE patient records were carefully studied and the clinical presentation, renal involvement, and autoantibody profile were recorded. Renal involvement was defined as proteinuria > 0.5 g/day or biopsy-proven lupus nephritis. We used the highest values for the anti-dsDNA titer and C3 level. The number of ACR criteria for SLE met, the SLE Disease Activity Index (SLEDAI), and the Systemic Lupus International Collaborating Clinics (SLICC)/ACR Damage Index were determined in each patient.

In patients with RA, clinical manifestations were determined in each patient: age at onset, functional status class according to ACR criteria, physician global assessment (PGA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), and severe disease. The PGA was the physician’s subjective opinion of disease severity on a visual analog scale of 0 (not severe) to 10 (most severe). ESR was determined by the Westergren method and CRP and RF were measured by nephelometry. The following variables were also evaluated: (1) history of total joint replacement (TJR) surgery, (2) history of hospitalization for RA for reasons other than TJR, (3) extraarticular manifestations such as nodules, vasculitis, eye and lung involvement, and (4) cervical spine involvement.

**DNA preparation.** Blood samples from all subjects were obtained for DNA extraction. Blood was collected in EDTA tubes and DNA was extracted using the method of proteinase K treatment and phenol/chloroform extraction.

**Polymorphism typing of the Fas promoter.** A polymerase chain reaction of a genomic DNA-restriction fragment length polymorphism using MvaI (PCR-RFLP) was used to determine genotypes of the Fas promoter –670. PCR was carried out using a forward primer 5’-CTACCTAAGGCTATCTACGGTTGC-3’ and a reverse primer 5’-GGCTGTCCATGTTGGTGATGCTGC-3’. Using a Perkin-Elmer-Cetus 9600 thermal cycler, samples were subjected to 30 cycles of 30 s at 94°C for denaturing, 30 s at 58°C for annealing, and 30 s at 72°C for extension and a final extension of 4 min at 72°C. PCR products were further subjected to RFLP analysis with the enzyme Mva I and separated on a 3% agarose gel. The digested A allele yielded a fragment of 232 bp and the G allele yielded a 188 bp fragment (Figure 1).

**Statistical analysis.** The genotype and allele frequencies in SLE patients were compared to those in control subjects using the chi-square test. The association of age at onset, number of ACR criteria for SLE, SLEDAI, SLICC/ACR Damage Index, anti-dsDNA antibody titer and C3 level with each genotype was analyzed by the Wilcoxon or Kruskal-Wallis test. The chi-square test was also used to evaluate comparison of the frequency of renal involvement and autoantibodies in each genotype. In patients with RA, the association of clinical features with each genotype was analyzed by the chi-square, Wilcoxon, or Kruskal-Wallis test. A p value was corrected by the number of characteristics studied and a p < 0.05 was considered significant.

**RESULTS**

**Fas promoter –670 polymorphisms among subjects.** The genotypes of the Fas promoter in patients with SLE and RA and controls did not deviate from the Hardy-Weinberg predictions. When the Fas promoter polymorphisms were compared between Korean and Caucasian healthy controls with respect to the genotype and allele frequencies, there were no significant differences (Table 1). The genotype distribution of the Fas promoter did not differ between SLE patients and control subjects (AA, GA, GG genotypes 31, 54, 15% vs 30, 55, 15% controls, respectively; chi-squared = 0.03, 2 df, p = 0.99) and between RA patients and control subjects (AA, GA, GG genotypes 38, 44, 18% vs 30, 55, 15% controls, respectively; chi-squared = 2.30, 2 df, p = 0.32) (Table 2). There was no difference in the genotype or allele frequencies among SLE and RA patients and controls.

**Clinical and laboratory analysis according to Fas promoter –670 genotypes.** There was no significant difference in age at onset, renal involvement, number of ACR criteria met, SLEDAI, SLICC/ACR Damage Index, anti-dsDNA, or C3 level in the lupus patients grouped according to Fas promoter –670 genotypes. With respect to autoantibody profiles, such as RF, anti-Sm, anti-Ro, anti-La, anticardiolipin antibodies, and lupus anticoagulant, there was no significant difference in the lupus patients based on the Fas promoter –670 polymorphisms (Tables 3 and 4). However, the frequency of the anti-RNP antibody was significantly different among the AA, GA, and GG groups (71, 25, 30%; chi-squared = 13.29, 2 df, p = 0.001) (Tables 4 and 5). In the

![Figure 1. Fas promoter –670 genotypes by PCR-RFLP. The genotypes AA (232 bp), GA (188,232 bp), and GG (188 bp) are shown. M: DNA size marker.](www.jrheum.org)
Table 1. Fas promoter –670 polymorphism between Korean and Caucasian healthy control subjects.

<table>
<thead>
<tr>
<th></th>
<th>Korean, n = 87 (%)</th>
<th>Caucasian, n = 86 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genotype frequencies</strong>a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>26 (30)</td>
<td>20 (23)</td>
</tr>
<tr>
<td>GA</td>
<td>48 (55)</td>
<td>44 (51)</td>
</tr>
<tr>
<td>GG</td>
<td>13 (15)</td>
<td>22 (26)</td>
</tr>
<tr>
<td><strong>Allele frequencies</strong>b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>74 (43)</td>
<td>84 (51)</td>
</tr>
<tr>
<td>A</td>
<td>100 (57)</td>
<td>88 (49)</td>
</tr>
</tbody>
</table>

a Chi-square test of heterogeneity, Korean vs Caucasian controls, chi-square = 3.27, 2 degrees of freedom (df); p = 0.20.

b Chi-square test of heterogeneity, Korean vs Caucasian controls, chi-square = 1.14, 1 df; p = 0.28.

Table 2. Genotype and allele frequencies of Fas promoter –670 polymorphism in RA, SLE patients and healthy controls.

<table>
<thead>
<tr>
<th></th>
<th>RA (n = 87)</th>
<th>SLE (n = 87)</th>
<th>Controls (n = 87)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genotype frequencies</strong>a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>33 (38)</td>
<td>27 (31)</td>
<td>26 (30)</td>
</tr>
<tr>
<td>GA</td>
<td>38 (44)</td>
<td>47 (54)</td>
<td>48 (55)</td>
</tr>
<tr>
<td>GG</td>
<td>16 (18)</td>
<td>13 (15)</td>
<td>13 (15)</td>
</tr>
<tr>
<td><strong>Allele frequencies</strong>b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>70 (40)</td>
<td>73 (42)</td>
<td>74 (43)</td>
</tr>
<tr>
<td>A</td>
<td>104 (60)</td>
<td>101 (58)</td>
<td>100 (57)</td>
</tr>
</tbody>
</table>

a Chi-square test of heterogeneity, RA vs controls, p = 32; SLE vs controls, p = 99.
b Chi-square test of heterogeneity, RA vs controls; p = 74; SLE vs controls, p = 1.00.

In patients with RA, there was no significant difference in age at onset, functional class (≥ 3), ESR, CRP, RF titer, the frequency of admission, PGA, extraarticular and cervical spine involvement, or frequency of joint operation to the Fas promoter –670 genotypes (data not shown).

**DISCUSSION**

SLE and RA are autoimmune disorders of unknown etiology. The pathogenesis of the diseases remains obscure, but genetic factors are considered to be contributory. With respect to the genetics of SLE and RA, there has been the possibility that non-HLA genes may play a pathogenetic role.

Apoptosis is a physiological process that regulates normal homeostasis, and apoptosis is likely to contribute to the pathogenesis of autoimmune diseases by the impaired elimination of autoreactive T and B cells12. Fas is considered to play an important role in the regulation of the immune system by deleting autoreactive peripheral lymphocytes. Fas, as an apoptosis gene, is one of the candidate genes in SLE and RA.

We analyzed a new genetic marker, MvaI polymorphism on the Fas promoter gene, in patients with SLE and RA. No difference was noted in genotype or allele frequencies among SLE and RA patients and controls. Interestingly, however, the frequency of anti-RNP antibodies was significantly different in SLE patients among the AA, GA, and GG groups (71, 26, and 30%) and the result in the second cohort replicated the association of the Fas promoter –670 polymorphism with development of anti-RNP antibodies shown in the first cohort. Although in patients with RA, there was no significant difference according to the Fas polymorphism, our results suggest that the Fas promoter –670 polymorphism could play a role in RA.

To our knowledge, there have been 2 studies on the association of the Fas promoter –670 polymorphism with SLE or RA11,13. Huang, et al11, showed a skewed distribution of MvaI genotypes in the first cohort of 103 Australian patients with RA, but this association was not confirmed in a second cohort. Although in patients with RA, there was no significant difference according to the Fas polymorphism, our results suggest that the Fas promoter –670 polymorphism could play a role in RA.

In SLE patients frequencies of MvaI alleles were not significantly different among the AA, GA, and GG groups (70% (19/27), 25% (11/44), 29% (4/14); chi-squared = 15.26, 2 df, p < 0.001) (Table 5). The result in the second cohort replicated the association shown in the first cohort.

**Table 3. Clinical analysis of the lupus patients according to the Fas promoter –670 genotypes.**

<table>
<thead>
<tr>
<th></th>
<th>AA (n = 27)</th>
<th>Fas Promoter –670 Genotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>GA (n = 47)</td>
</tr>
<tr>
<td>Age at onset, yrs</td>
<td>33.6 (2.2)</td>
<td>36.4 (1.8)</td>
</tr>
<tr>
<td>Renal disorder, % positive</td>
<td>37.0</td>
<td>25.5</td>
</tr>
<tr>
<td>No. of ACR criteria met</td>
<td>5.1 (1.3)</td>
<td>5.1 (1.4)</td>
</tr>
<tr>
<td>SLE disease activity index</td>
<td>9.9 (1.2)</td>
<td>11.3 (0.9)</td>
</tr>
<tr>
<td>SLICC/ACR Damage index</td>
<td>1.1 (0.2)</td>
<td>1.5 (0.2)</td>
</tr>
<tr>
<td>Anti-dsDNA titer, IU/ml</td>
<td>61 (25)</td>
<td>66 (16)</td>
</tr>
<tr>
<td>C3, mg/dl</td>
<td>66 (5)</td>
<td>58 (4)</td>
</tr>
<tr>
<td>C4, mg/dl</td>
<td>13 (1)</td>
<td>12 (1)</td>
</tr>
</tbody>
</table>

Values are the mean (SEM).
different versus controls, but the AA genotype was signifi-
cantly higher in SLE patients with photosensitivity or oral
ulcers than in SLE patients without these features. Coakley,
et al13 examined the association of the Fas promoter poly-
morphism with RA and Felty’s syndrome or large granular
lymphocyte leukemia. No difference was found in the geno-
type or allele frequencies between the groups. They found
no evidence that the polymorphism contributes to suscepti-
bility in these diseases.

In our study, there was no difference in genotypes or
allele frequencies between the groups. They found no
evidence that the polymorphism contributes to suscepti-
bility in these diseases.

In our study, there was no difference in genotypes or
allele frequencies between Caucasians and Koreans, but
the Fas promoter –670 polymorphism was suggested to play
a role. However, the function of the Fas promoter –670
polymorphism is still unknown, and geographic or ethnic
distribution of the polymorphism is also unknown. Studies
are needed to clarify the biological significance of the Fas
promoter polymorphism in other ethnic groups.

Our study has shown that the Fas promoter polymor-
phism does not confer susceptibility to SLE and RA, but Fas
promoter –670 is associated with development of anti-RNP
antibodies in SLE.

<table>
<thead>
<tr>
<th>Fas Promoter –670 Genotypes</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>GA</td>
</tr>
<tr>
<td>12/21 (57)</td>
<td>19/41 (48)</td>
</tr>
<tr>
<td>3/20 (15)</td>
<td>7/41 (17)</td>
</tr>
<tr>
<td>15/21 (71)</td>
<td>11/44 (25)</td>
</tr>
<tr>
<td>5/22 (23)</td>
<td>9/42 (25)</td>
</tr>
<tr>
<td>20/26 (77)</td>
<td>27/42 (64)</td>
</tr>
<tr>
<td>2/18 (11)</td>
<td>11/33 (33)</td>
</tr>
<tr>
<td>0/18 (0)</td>
<td>2/32 (6)</td>
</tr>
<tr>
<td>3/19 (11)</td>
<td>13/36 (36)</td>
</tr>
<tr>
<td>5/12 (42)</td>
<td>7/39 (24)</td>
</tr>
</tbody>
</table>

Anti-ENA antibodies were defined as at least one positivity in anti-Ro, La, RNP, Sm antibodies. n: tested number.

Table 5. Association between anti-RNP antibodies and Fas promoter –670

genotypes in SLE.

<table>
<thead>
<tr>
<th>Fas Promoter –670 Genotypes</th>
<th>AA</th>
<th>GA</th>
<th>GG</th>
</tr>
</thead>
</table>
| (A) First cohort
| Anti-RNP + | 15 (71) | 11 (25) | 3 (30) |
| Anti-RNP – | 6 (29) | 33 (75) | 7 (70) |
| (B) Second cohort
| Anti-RNP + | 19 (70) | 11 (25) | 4 (29) |
| Anti-RNP – | 8 (30) | 33 (75) | 10 (71) |

Values given are the number of subjects (%). A. Chi-square = 13.29, 2
degrees of freedom, p = 0.001. B. Chi-square = 15.26, 2 degrees of
freedom, p < 0.001.

REFERENCES
3. Salmon M, Scheel TD, Huissoon AP, et al. Inhibition of T cell
   apoptosis in the rheumatoid synovium. J Clin Invest 1997;
disease susceptibility genes in rheumatoid arthritis: principles and
5. Huang QR, Manolios N. Identification and
classification of polymorphism in the promoter region of the
human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-82.
   Rheumatism Association 1987 revised criteria for classification of
   Rheumatism Association 1987 revised criteria for classification of
8. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH.
   Derivation of the SLEDAI. A disease activity index for lupus
   patients. The Committee on Prognosis Studies in SLE. Arthritis
9. Gladman D, Gineler E, Goldsmith C, et al. The development and
   initial validation of the Systemic Lupus International Collaborating
   Clinics/American College of Rheumatology Damage Index for
   of Rheumatology 1991 revised criteria for the classification of
   Rheumatism Association 1987 revised criteria for classification of
12. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH.
   Derivation of the SLEDAI. A disease activity index for lupus
   patients. The Committee on Prognosis Studies in SLE. Arthritis
13. Gladman D, Gineler E, Goldsmith C, et al. The development and
   initial validation of the Systemic Lupus International Collaborating
   Clinics/American College of Rheumatology Damage Index for
   of Rheumatology 1991 revised criteria for the classification of
   global functional status in rheumatoid arthritis. Arthritis Rheum
15. Huang QR, Danis V, Lassere M, Edmonds J, Manolios N.
   Evaluation of a new Apo-1/Fas promoter polymorphism in
   rheumatoid arthritis and systemic lupus erythematosus patients.
16. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the
   homeostatic regulation of immune responses. Immunol Today
   JS. A Fas promoter polymorphism at position –670 in the enhancer
   region does not confer susceptibility to Felty’s and large granular